Comparative outcomes of a placenta-based tissue product to other LCD covered cellular and matrix-based products for the treatment of lower extremity diabetic ulcers: A Medicare real world evidence study
DOI:
https://doi.org/10.63676/qqygdq55Keywords:
CAMPs, medicare, Lower Extremity Ulcer, diabetes, placental allograft, real world evidence, wound, wound careAbstract
Objective: To compare clinical and economic outcomes of the Artacent placental allograft to 18 other covered cellular and matrix-based products (CAMPs) using data from a Medicare database.
Methods: We conducted a retrospective cohort study using data from the Centers for Medicare and Medicaid Services (CMS), employing a 1:1 matching procedure based on six pre-specified baseline covariates for Medicare patients who received Artacent or 18 other covered CAMPs for the treatment of lower extremity diabetic ulcer (LEDUs) between 2020 and 2023. LEDU episodes were constructed from claims data by linking sequential services until a 60-day clean period without LEDU related claims was observed, which signified the end of an episode. Outcomes assessed within each completed episode included major and minor amputations, as well as emergency department visits, hospital readmissions, or care transitions to other sites of service.
Results: A total of 2,226,571 episodes were identified in the CMS database, of which 1,192 LEDU episodes (596 in each cohort) met the study eligibility criteria and were analyzed. Rate of major and minor amputation in the Artacent group was 2.7% and 13.6% respectively as compared to 3.4% and 14.8% in the pooled CAMP group (p = 0.498 and 0.561 respectively). Visits or re-admissions to a hospital were also lower in the Artacent group; however, the results were not statistically significant.
Conclusion: Analysis of CMS data revealed similar outcomes when comparing Artacent placental allograft to 18 other covered CAMPs available on the market. It is reasonable to conclude that Artacent may be integrated into the treatment paradigms for LEDUs.
References
1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. https://www.cdc.gov/diabetes/data/statistics-report/index.html (accessed 28 October 2025)
2. Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023;330(1):62-75. https://doi.org/10.1001/jama.2023.105785
3. Carter MJ, DaVanzo J, Haught R, Nusgart M, Cartwright D, Fife CE. Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019. J Med Econ. 2023;26(1):894-901. https://doi.org/10.1080/13696998.2023.2232256
4. Agency for Healthcare Research and Quality. Hospital Admission versus Readmission Costs, 2020, 2020. https://www.ahrq.gov/data/infographics/hospital-readmission-costs.html (accessed 28 October 2025)
5. Franklin H, Rajan M, Tseng CL, Pogach L, Sinha A, Mph M. Cost of lower-limb amputation in U.S. veterans with diabetes using health services data in fiscal years 2004 and 2010. J Rehabil Res Dev. 2014;51(8):1325-1330. https://doi.org/10.1682/JRRD.2013.11.0249
6. Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024;40(3):e3644. https://doi.org/10.1002/dmrr.3644
7. Santema TB, Poyck PP, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2016;2(2):CD011255. https://doi.org/10.1002/14651858.CD011255.pub2
8. Wu S, Carter M, Cole W, et al. Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs). J Wound Care. 2023;32(Sup4b):S1-S31. https://doi.org/10.12968/jowc.2023.32.Sup4b.S1
9. Tettelbach W, Forsyth A. Current practices using cellular, acelluar and matrix-like products (CAMPs). Br J Nurs. 2024;33(4):S4-S8. https://doi.org/10.12968/bjon.2024.33.4.S4
10. Tettelbach W, Armstrong DG, Driver V, et al. Safeguarding access, fiscal responsibility and innovation: a comprehensive reimbursement framework for CAMPs to preserve the Medicare Trust Fund. J Wound Care. 2025;34(10):768-777. https://doi.org/10.12968/jowc.2025.0396
11. Tettelbach W, Armstrong D, Niezgoda J, et al. The hidden costs of limiting access: clinical and economic risks of Medicare’s future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination. J Wound Care. 2025;34(Sup5):S5-S14. https://doi.org/10.12968/jowc.2025.0120
12. Chen AC, Lu Y, Hsieh CY, Chen YS, Chang KC, Chang DH. Advanced Biomaterials and Topical Medications for Treating Diabetic Foot Ulcers: A Systematic Review and Network Meta-Analysis. Adv Wound Care (New Rochelle). 2024;13(2):97-113. https://doi.org/10.1089/wound.2023.0024
13. Centers for Medicare & Medicaid Services. Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. 2024. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=35041 (accessed 28 October 2025)
14. Armstrong DG, Tettelbach WH, Chang TJ, et al. Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015-2018). J Wound Care. 2021;30(Sup7):S5-S16. https://doi.org/10.12968/jowc.2021.30.Sup7.S5
15. Padula WV, Ramanathan S, Cohen BG, Rogan G, Armstrong DG. Comparative Effectiveness of Placental Allografts in the Treatment of Diabetic Lower Extremity Ulcers and Venous Leg Ulcers in U.S. Medicare Beneficiaries: A Retrospective Observational Cohort Study Using Real-World Evidence. Adv Wound Care (New Rochelle). 2024;13(7):350-362. https://doi.org/10.1089/wound.2023.0143
16. Tettelbach WH, Armstrong DG, Chang TJ, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022;31(Sup2):S10-S31. https://doi.org/10.12968/jowc.2022.31.Sup2.S10
17. Tettelbach WH, Driver V, Oropallo A, et al. Dehydrated human amnion chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. J Wound Care. 2024;33(Sup3):S7. https://doi.org/10.12968/jowc.2024.33.Sup3.S7
18. Wahab N, Tettelbach WH, Driver V, et al. The impact of dual-enrolee (Medicare/Medicaid) status on venous leg ulcer outcomes: a retrospective study. J Wound Care. 2024;33(12):886-892. https://doi.org/10.12968/jowc.2024.0174
19. Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775-1782. https://doi.org/10.1016/S0140-6736(18)30668-8
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. https://doi.org/10.1016/0021-9681(87)90171-8
21. Food and Drug Administration. Guidance for Industry: Non-Inferiority Clinical Trials to Establish Effectiveness, 2010. https://www.fda.gov/media/78504/download (accessed 30 September 2025)
22. Lazareth I, Moffatt C, Dissemond J, et al. Efficacy of two compression systems in the management of VLUs: results of a European RCT. J Wound Care. 2012;21(11):. https://doi.org/10.12968/jowc.2012.21.11.553
23. Stamas N, Vincent T, Evans K, et al. Use of healthcare claims data to generate real-world evidence on patients with drug-resistant epilepsy: practical considerations for research. J Health Econ Outcomes Res. 2024;11(1):57-66. https://doi.org/10.36469/001c.91991
Downloads
Published
Data Availability Statement
The data used in this study were obtained from the Centers for Medicare & Medicaid Services (CMS) Virtual Research Data Center (VRDC) under a data use agreement. These Research Identifiable Files (RIF) contain protected health information and are not publicly available. Access to the data requires CMS approval and an active Data Use Agreement.
Issue
Section
License
Copyright (c) 2025 International Journal of Tissue Repair
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
